Acute myelogenous leukemia (AML) originates from self-renewing leukemic stem cells
(LSCs), which represent the ultimate therapeutic target for AML. Recent studies have …

To clarify the cooperative roles of recurrently identified mutations and to establish a more
precise risk classification system in acute myeloid leukemia (AML), we comprehensively …

Acute myeloid leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an
ultimate therapeutic target in AML. Eradication of LSCs should be a critical and efficient …

When discussing treatment options for patients with acute leukemia, it is important to
acknowledge the impact of allogeneic hematopoietic cell transplantation (allo-HCT) or …

Abstract Background The phase 3 VIALE-A trial (NCT02993523) reported that venetoclax-
azacitidine significantly prolonged overall survival compared with placebo-azacitidine in …

We investigated the significance of surface antigen expression for prognosis by focusing on
a specific subtype, AML with t (8; 21). The investigation included 144 patients with AML with t …

Long-term survival in patients with acute myeloid leukemia (AML) remains low, and current
treatment modalities are inadequate. Milademetan (DS-3032, RAIN-32), a small-molecule …

Background Until recently, no effective targeted therapies for FLT3-mutated (FLT3 mut+)
relapsed/refractory (R/R) acute myeloid leukemia (AML) were available in Japan. The FLT3 …

Seventy to 80% of patients with acute myeloid leukemia (AML) achieve complete remission
following intensive chemotherapy, but more than 50% of patients in remission subsequently …

Background Venetoclax plus azacitidine is indicated in the USA for the treatment of newly
diagnosed acute myeloid leukaemia in older patients (≥ 75 years) or those ineligible for …